We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Fingerprint for Insulin Sensitivity Could Diagnose Diabetes Before Disease Develops

By LabMedica International staff writers
Posted on 28 May 2025

Insulin is a hormone essential for regulating blood sugar levels, and its dysfunction is a key factor in the development of diabetes. More...

Insulin resistance, a condition where the body's cells do not respond effectively to insulin, is a defining feature of type 2 diabetes, a disease known for its varied pathophysiology. Gaining a deeper understanding of the molecular mechanisms behind insulin resistance and how it correlates with individual traits is vital for the advancement of precision medicine in type 2 diabetes. Now, a breakthrough in this area offers promising potential for more effective treatments and the possibility of earlier detection of type 2 diabetes.

Researchers at the University of Copenhagen (Copenhagen, Denmark) have uncovered significant findings regarding how the body processes insulin. This discovery could lead to improved treatment options for type 2 diabetes and the potential for diagnosing the condition earlier, possibly even before it manifests. In a recent publication in the journal Cell, the researchers revealed that every individual exhibits unique levels of insulin resistance at the molecular level. This ‘molecular fingerprint’ of insulin sensitivity challenges the traditional view that people are simply categorized as either healthy or suffering from type 2 diabetes.

The breakthrough was achieved using advanced proteomics, a protein analysis technique, to investigate the impact of insulin on muscle tissue. By examining muscle biopsies from over 120 individuals, the team mapped molecular alterations in response to insulin. Their findings indicated that certain proteins undergo consistent changes as insulin resistance progresses. These molecular signatures could enable earlier identification of individuals at risk, potentially even before the onset of clinical symptoms. Additionally, the researchers were able to use these molecular profiles to accurately predict how well the body responds to insulin.

“We found huge variation in insulin sensitivity, even among people considered healthy and among those diagnosed with type 2 diabetes. There are even some individuals living with type 2 diabetes who respond better to insulin than healthy individuals. Our study highlights the need to move beyond separating people into two boxes and recognize individual variation,” said Associate Professor Atul Deshmukh, one of the senior authors of the research. “We show which proteins are altered as insulin resistance progresses, and that knowledge could lay the groundwork for more targeted treatments, potentially even before type 2 diabetes develops.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automatic CLIA Analyzer
Shine i6000
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.